CTOR
Sign in
Citius Oncology, Inc.
Save
75.58M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue